Akorn enters premix contract

BUFFALO GROVE -- Akorn Inc. announced on Thursday that it signed a five-year supply agreement with Fresenius Kabi for a premix product. Premix medications are ready to use intravenous drug products, which eliminate compounding steps in the pharmacy or at the point of care. Buffalo Grove-based Akorn will be responsible for development, marketing and distribution of the undisclosed product. Fresenius Kabi will make it in Halden, Norway.